Stock BJDX BLUEJAY DIAGNOSTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Bluejay Diagnostics, Inc.

Equities

BJDX

US0956333019

Delayed Nasdaq
Other stock markets
 20:16:40 24/05/2024 BST 		5-day change 1st Jan Change
0.49 USD -1.61% Intraday chart for Bluejay Diagnostics, Inc. -15.52% -59.84%
04-02 Bluejay Diagnostics, Inc. Appoints Neil Dey as Principal Financial and Accounting Officer CI
03-28 Bluejay Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bluejay Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients
CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Bluejay Diagnostics, Inc. Updates Symphony IL-6 Regulatory Strategy
CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
BLUEJAY DIAGNOSTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America
CI
BLUEJAY DIAGNOSTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Bluejay Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
BLUEJAY DIAGNOSTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Bluejay Diagnostics Presents Positive Clinical Results for its Symphony IL-6 Test at AACC 2022
CI
Earnings Flash (BJDX) BLUEJAY DIAGNOSTICS Posts Q2 Revenue $249,040
MT
Bluejay Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Bluejay Diagnostics, Inc. Completes Planned Clinical Studies for Symphony IL-6 Test
CI
Bluejay Diagnostics Says FDA Agrees to Study new Regulatory Pathway for Symphony IL-6 Test; Shares Rise Pre-Bell
MT
Bluejay Reports FDA Agrees to Consider Its Plan to Pursue A De Novo Regulatory Pathway for the Symphony II-6 Test
CI
BLUEJAY DIAGNOSTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Earnings Flash (BJDX) BLUEJAY DIAGNOSTICS Reports Q1 Loss $-0.10
MT
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BJDX Stock
  4. News Bluejay Diagnostics, Inc.
  5. Highlights